Loading...

INTERPACE BIOSCIENCES INC Capital Structure Changes 8-K Filing

NTRP

INTERPACE BIOSCIENCES INC

()

2026 8-K

Financial Results Report

Financial Statements

Management Changes

Financial Restatement

Test Discontinuation

External Links:

On January 20, 2026, Interpace Biosciences, Inc. announced preliminary unaudited revenue for the year ended December 31, 2025, and reported that all outstanding shares of its Series C Preferred Stock were converted into common stock.

AI Assistant

INTERPACE BIOSCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.